drugset
drugset / Trial / NCT05735249

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects

NCT05735249 ↗

Phase 1 Completed 94 enrolled Arisan Therapeutics, Inc. United States Department of Defense · collab
RandomizedSequentialQuadruple-blindTreatment

Summary

ARN-75039 is proposed for the treatment of subjects with LASV infection, Lassa hemorrhagic fever, a potentially fatal human disease associated with Lassa viruses, with the most significant unmet medical need. ARN-75039-101 study was a randomized, double-blind, placebo-controlled study that assessed the safety, tolerability, and PK of escalating single and multiple doses of ARN 75039 when administered by the oral route in healthy adult subjects in six single ascending dose (SAD - Part 1) cohorts and five multiple ascending dose (MAD - Part 2) cohorts.

Timeline

Start
2023-01-23
Primary completion
2025-03-28
Completion
2025-03-28

Drugs

EvaluationDrugModalityDoseRoute
Subject ARN-75039 Small molecule — Oral

Indications

No indication recorded.